Economist Peter Schiff criticizes the disconnect between silver's 35% December surge and silver mining stocks' modest 11% gain, arguing mining stocks should have doubled given their typical leveraged exposure to the metal. Despite silver's historic rally and 154.57% year-to-date gains, major mining stocks and ETFs have significantly underperformed, presenting what Schiff views as an attractive buying opportunity.

Silver has rallied 152% year-to-date, its strongest performance since 1978, driven by industrial demand and a structural supply deficit. The market is experiencing backwardation due to tight physical supplies, with China's export restrictions adding further pressure. Analysts predict prices could test $85-$100 per ounce as deficits widen, benefiting both silver producers and junior miners.

Silver has surged 112% in 2025, reaching an all-time high above $61 per ounce. Silver miners have become explosive investment opportunities, with some ETFs and mining stocks delivering over 140% returns year-to-date.

New Pacific Metals Corp. announced a bought deal financing of 9.9 million common shares at C$3.55 per share, raising approximately C$35.1 million. Silvercorp Metals will participate by subscribing to 2,776,950 shares, which will represent about 28.05% of outstanding shares.

New Pacific Metals (NEWP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how Hecla Mining (HL) and New Pacific Metals Corp. (NEWP) have performed compared to their sector so far this year.

VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) -- New Pacific Metals Corp. (TSX: NUAG; NYSE American: NEWP) (“New Pacific” or the “Company”) announced today that it has closed (the "Closing") the bought deal financing that was previously announced on September 25, 2023. A total of 13,208,000 common shares of the Company (the “Offered Shares”) were sold under the Offering (as defined below) at a price of C$2.65 per Offered Share (the “Issue Price”) for total gross proceeds of approximately C$35 million (the “Offering”). The Offering was through a syndicate of underwriters (the “Underwriters”), pursuant to the terms of an underwriting agreement between the Company and the Underwriters dated September 26, 2023 (the "Underwriting Agreement").

Not for Distribution in the United States or to U.S. Newswire Services

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 400 points on Tuesday. The Dow traded down 1.19% to 33,601.60 while the NASDAQ fell 1.48% to 13,074.97. The S&P 500 also fell, dropping, 1.42% to 4,276.00. Check This Out: DraftKings To Rally Around 35%? Here Are 10 Other Analyst Forecasts For Tuesday   Leading and Lagging Sectors Energy shares fell by just 0.01% on Tuesday. In trading on Tuesday, utilities shares tumbled by 2%.   Top Headline United Natural Foods Inc (NYSE: UNFI) reported mixed results for its fourth quarter on Tuesday. United Natural Foods reported fourth-quarter FY23 sales growth of 2% year-on-year to $7.417 billion, missing the analyst consensus of $7.47 billion. Adjusted EPS of $(0.25) beat the analyst consensus estimate of $(0.28). United Natural Foods sees FY24 sales of $30.9 billion-$31.5 billion, against the consensus of $31.03 billion. The company expects FY24 adjusted EPS of $(0.88)-$0.38 versus the consensus of $2.56.   Equities Trading UP Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares shot up 442% to $24.01 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome. Shares of Femasys Inc. (NASDAQ: FEMY) got a boost, shooting 260% to $1.1950 after the company received FDA 510(k) ...

Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome. Femasys Inc. (NASDAQ: FEMY) surged 244% to $1.1410 after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares gained 77.3% to $18.50. Alfasigma agreed to acquire Intercept Pharmaceuticals for $19.00 per share in cash. Immunovant, Inc. (NASDAQ: IMVT) jumped 75.6% to $35.60 after the company announced initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results. Tharimmune Inc (NASDAQ: THAR) shares gained 39.5% to $0.3090 after falling around 5% on Monday. Acasti Pharma Inc. (NASDAQ: ACST) gained 27.1% to $2.2250. Acasti announced a $7.5 million private placement equity financing. Cano Health, Inc. (NYSE: CANO) surged 24.2% to $0.3380. Cano Health said it sold substantially all of the assets associated with the operation of Cano Health's senior-focused primary care centers in Texas and Nevada to CenterWell Senior Primary Care. Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) gained 23.6% to $3.5499. Bullfrog AI announced data from its preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for glioblastoma. Avalo Therapeutics, Inc. (NASDAQ: AVTX) gained 21.9% to $0.1987 after jumping over 36% on Monday. Avalo Therapeutics reported the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance. Adaptive Biotechnologies Corporation (NASDAQ: ADPT) shares climbed 21.2% to $6.16. Adaptive recently announced the launch ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 0.96% to 33,681.79 while the NASDAQ fell 1.24% to 13,106.70. The S&P 500 also fell, dropping, 1.20% to 4,285.24. Check This Out: DraftKings To Rally Around 35%? Here Are 10 Other Analyst Forecasts For Tuesday   Leading and Lagging Sectors Energy shares fell by just 0.4% on Tuesday. In trading on Tuesday, communication services shares tumbled by 1.5%.   Top Headline Cintas Corporation (NASDAQ: CTAS) reported better-than-expected earnings for its first quarter on Tuesday. The company posted first-quarter FY24 revenue growth of 8% year-on-year to $2.34 billion, meeting the analyst consensus estimate. EPS of $3.70 beat the analyst consensus estimate of $3.67. Cintas raised FY24 revenue outlook from $9.35 billion - $9.50 billion to $9.40 billion - $9.52 billion, against the consensus of $9.50 billion. The company also raised FY24 EPS outlook from $13.85 - $14.35 to $14.00 - $14.45 versus an estimate of $14.42.   Equities Trading UP Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares shot up 385% to $21.48 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome. Shares of Femasys Inc. (NASDAQ: FEMY) got a boost, shooting 261% to $1.20 after the ...

Not for Distribution in the United States or to U.S. Newswire Services